These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21751080)

  • 1. Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina.
    Eizenberg P; Booy R; Naser N; Mason G; Stamboulian D; Weber F
    Adv Ther; 2011 Aug; 28(8):640-9. PubMed ID: 21751080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acceptance and opinions of Intanza/IDflu intradermal influenza vaccine in the Czech Republic and Turkey.
    Prymula R; Usluer G; Altinel S; Sichova R; Weber F
    Adv Ther; 2012 Jan; 29(1):41-52. PubMed ID: 22228256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptability of Intanza® 15 μg intradermal influenza vaccine in Belgium during the 2010-2011 influenza season.
    Dhont PA; Albert A; Brenders P; Podwapinska A; Pollet A; Scheveneels D; Tihon F; Verheyden I; Victor J; Samson SI
    Adv Ther; 2012 Jun; 29(6):562-77. PubMed ID: 22678831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: a survey of general practitioners and the general public in France and Germany.
    Arnou R; Frank M; Hagel T; Prébet A
    Adv Ther; 2011 Jul; 28(7):555-65. PubMed ID: 21626269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intanza(®): a new intradermal vaccine for seasonal influenza.
    Atmar RL; Patel SM; Keitel WA
    Expert Rev Vaccines; 2010 Dec; 9(12):1399-409. PubMed ID: 21105776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intanza (®) 9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age.
    Leroux-Roels I; Weber F
    Hum Vaccin Immunother; 2013 Jan; 9(1):115-21. PubMed ID: 23442585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
    Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
    Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluzone(®) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults.
    Ansaldi F; de Florentiis D; Durando P; Icardi G
    Expert Rev Vaccines; 2012 Jan; 11(1):17-25. PubMed ID: 22149703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptance and safety of the intradermal influenza vaccine among the elderly in Italy: an on-field national study.
    Durando P; Alicino C; Alberti M; Sticchi L; Turello V; Marensi L; Caiazzo AL; Panico MG; Giugliano F; Parlato A; Peluso F; Sgricia S; Icardi G;
    Adv Ther; 2012 Apr; 29(4):312-26. PubMed ID: 22529024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of Intanza(®)/IDflu(®) intradermal influenza vaccine in South Korean adults: a multicenter, randomized trial.
    Hoon Han S; Hee Woo J; Weber F; Joo Kim W; Ran Peck K; Il Kim S; Hwa Choi Y; Myung Kim J
    Hum Vaccin Immunother; 2013 Sep; 9(9):1971-7. PubMed ID: 23778938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability of fluzone intradermal vaccine to patients and vaccine administrators.
    Foy JE; Hendriksz T; Malouf P; Tobin A
    J Am Osteopath Assoc; 2013 Feb; 113(2):134-43. PubMed ID: 23412675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers.
    Coleman BL; McNeil SA; Langley JM; Halperin SA; McGeer AJ
    Vaccine; 2015 Nov; 33(48):6635-40. PubMed ID: 26529074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.
    Leroux-Roels I; Vets E; Freese R; Seiberling M; Weber F; Salamand C; Leroux-Roels G
    Vaccine; 2008 Dec; 26(51):6614-9. PubMed ID: 18930093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nine μg intradermal influenza vaccine and 15 μg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults.
    Nougarede N; Bisceglia H; Rozières A; Goujon C; Boudet F; Laurent P; Vanbervliet B; Rodet K; Hennino A; Nicolas JF
    Hum Vaccin Immunother; 2014; 10(9):2713-20. PubMed ID: 25483667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.
    Arnou R; Icardi G; De Decker M; Ambrozaitis A; Kazek MP; Weber F; Van Damme P
    Vaccine; 2009 Dec; 27(52):7304-12. PubMed ID: 19849996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.
    Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M
    J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination.
    Morelon E; Pouteil Noble C; Daoud S; Cahen R; Goujon-Henry C; Weber F; Laurent PE; Kaiserlian D; Nicolas JF
    Vaccine; 2010 Oct; 28(42):6885-90. PubMed ID: 20709000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized control trial comparing immunogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine.
    Coleman BL; McGeer AJ; Halperin SA; Langley JM; Shamout Y; Taddio A; Shah V; McNeil SA
    Vaccine; 2012 Sep; 30(44):6287-93. PubMed ID: 22902784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
    Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
    Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement.
    Ansaldi F; Durando P; Icardi G
    Expert Opin Biol Ther; 2011 Mar; 11(3):415-27. PubMed ID: 21299438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.